Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Toward new horizons: The future of bisphosphonate therapy
Allan Lipton
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
53
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Toward new horizons: The future of bisphosphonate therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Androgen Deprivation Therapy
40%
Antitumor Activity
20%
Bisphosphonate Therapy
100%
Bisphosphonates
80%
Bone Metastasis
20%
Bone Mineral Density
20%
Breast Cancer
40%
Cancer Treatment-induced Bone Loss
60%
Cincinnati
20%
Clinical Benefit
20%
Clinical Data
20%
Clinical Trials
60%
Clodronate
40%
Disease Progression
20%
Early Breast Cancer
20%
Early Cancer
20%
Estrogenic
20%
Gambling
20%
Hanover
20%
High Risk
20%
Hormonal Therapy
20%
Malignant Bone Disease
40%
Model Trial
20%
Neoadjuvant Endocrine Therapy
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Novartis
40%
Oncology Setting
20%
Patients with Breast Cancer
20%
Placebo
20%
Princeton
20%
Prostate Cancer
60%
Prostate Cancer Cells
20%
Significant Benefit
20%
Standard of Care
20%
Treatment Duration
20%
United Europe
20%
United States
20%
Zoledronic Acid
100%
Zometa
40%
Pharmacology, Toxicology and Pharmaceutical Science
Letrozole
14%
Risedronic Acid
28%